USPTO serial 79372254
HOVILPRI
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 22, 2024
- Examiner
- SEVERSON, JUSTIN
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with HOVILPRI?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
F. William McLaughlin
F. William McLaughlin Wood Phillips500 W MadisonSuite 1130Chicago, IL 60661Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Antivirals; antivirals for topical use; Medicine for treatment of infectious diseases, viral infections, herpes simplex virus infections, Medicine for prophylaxis of infectious diseases, viral infections, herpes simplex virus infections; Medicines for treatment of infectious diseases, viral infections, herpes simplex virus infections for human purposes, Medicines for prophylaxis of infectious diseases, viral infections, herpes simplex virus infections for human purposes; Medicines for treatment of viral infections for veterinary purposes; Medicines for dental purposes; medicated eye lotions for medical use; medicated eye ointment for medical use; Creams for dermatological use; Dermatological-pharmaceutical products; Medicated lip creams; Medicated skin creams; Medicated skin lotions; Medicinal preparations for the treatment of infectious diseases; Medicated ointments for application to the skin for treating dermatological conditions; Medicated preparations for treating dermatological conditions; Medicated ointments for treating dermatological conditions; medicated preparations for the treatment of herpes of the lips; Ophthalmological preparations; Ophthalmic preparations; Ophthalmologic preparations; Pharmaceutical preparations for ophthalmological use; Pharmaceutical preparations for use in ophthalmology; Pharmaceutical products for ophthalmological use; Topical ophthalmic anti-infective substances for the treatment of infections; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical lip ointments; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations and substances for use in gynecology; Pharmaceutical preparations and substances for use in urology; Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations for the treatment of diseases of the genitourinary system; Pharmaceutical preparations for the prevention of diseases of the genitourinary system; Pharmaceutical preparations for skin wounds; Sulfonamides being medicines; Sulfonamide preparations; Transdermal patches for medical treatment of infectious diseases, viral infections, herpes simplex virus infections; Pharmaceutical lipsalves; Antiviral drugs for treating herpes simplex virus infections; Preparations for the treatment of genital herpes; Medicinal preparations for the treatment of herpes simplex virus infections; medicinal preparations for the treatment of labial herpes; medicinal preparations for the treatment of mucosal herpes; Pharmaceutical preparations for the treatment of herpes simplex virus infections; Pharmaceutical preparations for skin lesions; Sulfonamides for treatment of infectious diseases, viral infections, herpes simplex virus infections, Sulfonamides for prophylaxis of infectious diseases, viral infections, herpes simplex virus infections, Salts of sulfonamides for treatment of infectious diseases, viral infections, herpes simplex virus infections, Salts of sulfonamides for prophylaxis of infectious diseases, viral infections, herpes simplex virus infections; Pharmaceutical formulations in the form of tablets for treatment of infectious diseases, viral infections, herpes simplex virus infections, Pharmaceutical formulations in the form of tablets for prophylaxis of infectious diseases, viral infections, herpes simplex virus infections; Pharmaceutical formulations in the form of solutions for treatment of infectious diseases, viral infections, herpes simplex virus infections, Pharmaceutical formulations in the form of solutions for prophylaxis of infectious diseases, viral infections, herpes simplex virus infections; Pharmaceutical formulations in the form of suspensions for treatment of infectious diseases, viral infections, herpes simplex virus infections, Pharmaceutical formulations in the form of suspensions for prophylaxis of infectious diseases, viral infections, herpes simplex virus infections; Pharmaceutical formulations for intra-veneous application for treatment of infectious diseases, viral infections, herpes simplex virus infections, Pharmaceutical formulations for intra-veneous application for prophylaxis of infectious diseases, viral infections, herpes simplex virus infections; Antiviral drugs for treating of sexually transmittable diseases; Medicinal preparations for the treatment of sexually transmittable diseases. | ACTIVE | — |
| 010 | Medical devices for intra-vaginal use for treatment of infectious diseases, viral infections, herpes simplex virus infections; Medical devices for intra-vaginal use for prophylaxis of infectious diseases, viral infections, herpes simplex virus infections; medical devices for intra-vaginal application of anti-virals; medical devices for intra-vaginal application of sulfonamides | ACTIVE | — |
| 041 | Organization of seminars and conventions in the field of medicine; Publication of scientific information journals; publishing of online electronic publications; publishing of electronic publications; providing education courses in the field of science; Organization of seminars and conventions in the field of virology. | ACTIVE | — |
| 044 | Pharmaceutical consultancy services; consultancy and information services relating to medical products; providing health information; information services relating to health care; provision of health information; medical information services provided via the internet | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by AIC316 GmbH
- Other trademarks owned by AIC316 GmbH
- Other trademarks owned by AIC316 GmbH
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 041
- Other trademarks in Class 044
- Similar marks named HOVILPRI
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 5, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Apr 12, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 26, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Mar 26, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jan 22, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Oct 22, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Oct 22, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 6, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 6, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 17, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 27, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 20, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 20, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 20, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 23, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Dec 28, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Dec 28, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 20, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 19, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 19, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 27, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 23, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 22, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |